Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 143

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 143
---
ine and methadone is limited by their treatment regimens and inherent risks of abuse, placing significant requirements and regulations on practitioners. In addition to these limitations, current treatment options are not considered to be highly effective; approximately 75% of patients undergoing Opioids Use Disorder, or OUD, therapy experience relapse within one year of treatment. For abuse of other substances, such as cocaine or methamphetamine, no pharmacological agents have been approved for treatment. Despite the limitations of current treatment options for AUD, we believe that very few psychedelic treatment candidates are being developed to address this problem. Weight loss, Obesity, and Metabolic Syndrome The prevalence of obesity has reached epidemic proportions, with approximately one billion people worldwide projected to be affected by 2030, including approximately 1 in 5 women and 1 in 7 men, according to the recently published World Obesity Atlas 2022 by the World Obesity Federation. Obesity is a chronic disease that has been linked to several conditions, including cardiovascular disease (CVD), type 2 diabetes (T2D), and non-alcoholic fatty liver disease (NAFLD). While multiple metabolic factors have been associated with the development of obesity, the underlying molecular mechanisms are not yet fully understood. Despite the gravity of the situation, the lack of effective anti-obesity treatments poses a significant challenge. 87 Several factors, including eating habits, fast food consumption, personality traits, depression, and genetics, have been implicated in the etiologies of obesity. Recently, the notion of food addiction has gained attention as a potential explanation for the obesity epidemic, with links observed between food addiction and substance-related and eating disorders (most prominently binge-eating). The similarities between food addiction and drug dependence, including an overactive response in the mesolimbic reward circuits, contribute to an inability to control food intake and maintain weight loss, leading to a cycle of binge eating that is difficult to break. This pattern is similar to what is seen in drug addiction, where the activation of these reward circuits contributes to an inability to control drug use. The similarities between food addiction and drug dependence suggest that similar therapeutic approaches may be effective in treating both obesity and addictive disorders. Psychedelics, including lysergic acid diethylamide (LSD), mescaline, psilocybin, and N,N-dimethyltryptamine (DMT), interact with the serotonin receptors, particularly 5-HT2C, 5-HT2A, and 5-HT1A. These receptors are densely located in